Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

• Status: Terminated
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. Relapse more than 6 months following first line chemotherapy is regarded as platinum/taxane sensitive disease. Reinduction chemotherapy with platinum/taxane is known to be an effective treatment option. Therapy induced anemia is a common problem resulting in decrease of quality of life. The rationale of this trail is to evaluate the effects of epoetin alpha on reduction of therapy induced anemia, rate of transfusions and on quality of life.

• Phase: Phase 3

Details

• Lead Sponsor: AGO Study Group
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Epoetin Alfa; Paclitaxel

Criteria

Inclusion Criteria:

• Relapse longer than 6 months after termination of platinum/taxane based first line chemotherapy

• Previously histologically confirmed cancer of: ovary, fallopian tube, peritoneum

• measurable and evaluable lesions by ultrasound, computer-tomography or MRI

• Performance status ECOG < 2 or karnofsky index > 60%

• normal organ function

Exclusion Criteria:

• more than 1 chemotherapy prior enrollment

• ongoing treatment with epoetin alpha or related drugs

• history of thrombosis or embolism during the past 12 months prior enrollment

• ileus

• left ventricular failure > NYHA classification > 2

• Ongoing toxicity of any kind (> CTC Grad II)